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ABSTRACT

Detecting Adverse Drug Events using a Deep Neural Network Model

Saminur Islam
Adverse drug events represent a key challenge in public health, especially with respect to drug safety profiling and drug surveillance. Drug-drug interactions represent
one of the most popular types of adverse drug events. Most computational approaches
to this problem have used different types of drug-related information utilizing different
types of machine learning algorithms to predict potential interactions between drugs.
In this work, our focus is on the use of genetic information about the drugs, in particular, the protein sequence and protein structure of drug protein targets to predict
potential interactions between drugs. We collected information on drug-drug interactions (DDIs) from the DrugBank database and divided them into multiple datasets
based on the type of information, such as, chemical structure, protein targets, side
effects, pathways, protein-protein interactions, protein structure, information about
indications. We proposed a similarity-based Neural Network framework called protein sequence-structure similarity network (S3N), and used this to predict the novel
DDI’s. The drug-drug similarities are computed using different categories of drug
information based on multiple similarity metrics. We compare the results with those
from the state-of-the art methods on this problem. Our results show that proposed
method is quite competitive, at times outperforming the state-of-the-art. Our performance evaluations on different datasets showed the predictive performance as follows:
Precision 91%-98%, Recall 90%-96%, F1 Score 86%-95%, AUC 88%-99% Accuracy
86%-95%. To further investigate the reliability of the proposed method, we utilize
158 drugs related to cardiovascular disease to evaluate the performance of our model

and find out the new interactions among the drugs. Our model showed 90% accuracy
of detecting the existing drug interactions and identified 60 new DDI’s for the cardiovascular drugs. Our evaluation demonstrates the effectiveness of S3N in predicting
DDI’s.
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CHAPTER 1
Introduction
Given the increasing number of medications that are being consumed concurrently by
individuals, it is becoming more and more important to know more about the drugs
we take. With this increased potential for polypharmacy, there is a corresponding
increase in the chance of adverse events involving medications. It has been revealed
that drugs may interact with others when they are taken together, and unexpected
drug-drug interactions (DDIs) may lead to unexpected adverse drug events[48, 18].
The sheer number of people taking more than one medication in a given day has
made the issue of drug-drug interactions a major public health problem. So, the
more DDIs we know, the more we could take necessary measures to avoid unforeseen
adverse drug events.

1.1

Significance of DDI problem

Recent advances in biomedical research have generated a large volume of drug-related
data. To effectively handle this enormous amount of data, many initiatives have been
introduced to help researchers make sense of the massive data sets. Drug knowledge
bases such as Drug Bank, SIDER, PDB, STITCH, SMILES, Protein Data Bank, and
others have emerged as a result of this. These knowledge bases contain a variety
of drug-related information, such as genetic sequences, protein structures, drug side
effects, chemical structures, drug indications, etc. Thus, several approaches have
been proffered to utilize the information from these different sources to predict potential interactions between drugs [29, 31, 57, 43, 50]. DrugBank is perhaps one of
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the most credible databases of known DDIs [17],[20],[33] and contains information
on over 300,000 DDIs. However, the number of drug-drug interactions is less than
1% of the total possible drug pairs that exist in DrugBank. DDI’s are known as
the unwanted side effects resulting from the concurrent consumption of two or more
drugs[36],[47],[35]. When a doctor prescribes several drugs simultaneously for a patient, this may cause irreparable side effects. The effects of drugs on each other may
lead to other illnesses or even death. These side effects are particularly noticeable in
the elderly, or in persons with challenging diseases, such as cancer patients, who take
many different drugs daily. Given the relevance of this in an individual’s health, and
to public health in general, there is a critical need for more accurate and effective
computational methods for understanding DDIs and how to predict them.

1.2

Steps taken by the researchers

However, researchers have developed several computational prediction strategies to
address adverse drug events by detecting DDIs in recent years. Among the different approaches, machine learning-based DDI prediction has been used popularly
for predicting the DDI’s with reduced time and cost[32, 33, 34, 17, 38, 59, 62, 61].
Many machine learning-based DDI prediction methods have been proposed, and are
roughly classified into four categories: similarity-based methods, network-based methods, matrix factorization-based methods, and ensemble learning-based methods[12].
The similarity-based methods are one major category among these methods.

1.3

Problem Statement

A drug interaction occurs when two (or more) drugs interact, or when a drug interacts
with food, beverage, or supplement. Drug interactions can reduce the effectiveness
of your medication, induce unanticipated side effects, or boost the impact of a drug.
Some drug interactions can be dangerous to your health. It’s possible that reading
the label every time you use a nonprescription or prescription drug, as well as learning
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about drug interactions, will save your life[1]. A drug-drug interaction may increase or
decrease the effects of one or both drugs. Clinically significant interactions are often
predictable and usually undesired (see Some Drugs With Potentially Serious DrugDrug Interactions)[66]. Adverse effects or therapeutic failure may result. Rarely,
clinicians can use predictable drug-drug interactions to produce a desired therapeutic
effect[52]. Moreover, Drug interaction is a leading cause of adverse drug events and
a major obstacle for current clinical practice[66]. Adverse drug events (ADEs), the
unintended drug side effects, have led to a major public health burden. In the United
States alone, > 500,000 serious ADEs were reported annually to the US Food and
Drug Administration (FDA) during the past 5 years [2]. Here we review the recent
developments in addressing the challenge of adverse drug events within the range of
different domains. And also we construct a set of data sets to search for new DDI’s.
Patients with cardiovascular diseases (CVD) are at high risk of experiencing
DDIs[6]. A scientifically driven and reasonable approach to drug interactions can
reduce the risk of harmful effects and enhance patient outcomes. Cardiovascular
drugs are used to treat a variety of illnesses, but there are often significant variances
in treatment response and dosage requirements between patients. Treatment that
works for one person may be useless or even hazardous for another[46]. Patients with
pre-existing cardiac problems are frequently prescribed multiple drugs, such as anticoagulants and antiarrhythmics, which can interact with a range of chemotherapies
in real and prospective ways. The focus of treatment in cardio-oncology has evolved
from reactive to proactive care as the profession has progressed[70]. Because the therapeutic window for most chemotherapies is so short, these drug-drug interactions that
may improve or decrease chemotherapeutic efficacy or predispose patients to major
unexpected side effects should be given considerable consideration[70]. So a system
of predicting the interaction among drugs in cardiovascular disease and planning an
individual patients’ drug therapies is in dire need.
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1.4

Objective

After looking through the published work for predicting drug-drug interactions, we
discovered that none of the algorithms meet the goals. Because detecting DDIs in a
clinical test is extremely challenging. Many DDIs are dose-dependent, and the nature
of the drug approval process, as well as inherent genetic and demographic diversity,
can all cause DDI Recognition to be delayed[45]. The primary objective of most
machine learning and deep learning approaches is to identify interactions. In the current research on DDI prediction, the is surprisingly little information on medications
used to address the problem. The main objective of most machine learning and deep
learning approaches is to identify interactions. The current research on DDI prediction has utilized only a small amount of drug information. Our goal is to create a
deep neural network framework that takes advantage of all available pharmacological
information, including chemical structure, protein structure, protein sequence, side
effects, interactions between proteins, pathways, etc.
Following the development of a deep learning framework for predicting potential
novel DDIs, we use the methodology for the cardiovascular disease problem. Considering how many drugs are available on the market today and how many people take
different medications based on prescriptions, it is likely that there will be multiple
interactions, including interactions with cardiovascular drugs and interactions with
other medications. Our study will look at both types of interactions and see how
effective the clinical trial is at improving patients’ drug regimes.

1.5

Thesis Organization

In this thesis, we investigate how this can be predicted from different categories of
drug information. We organize our work as follows: In the next chapter, we review
related work. In the third chapter, we discussed our proposed methodology. Chapter
four describes the extension of our work on the DDI prediction model and its application in cardiovascular drug interaction prediction. In Chapter five, we describe
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our experimental studies and observed results for drug-drug interaction prediction
and how we plan to use our proposed method to discover drug interactions for cardiovascular drugs. Chapter six would represent the discussions and limitations of
our proposed methodology and possible improvements. Finally, Chapter seven will
present the Conclusions and Future Work.

5

CHAPTER 2
Related Works
Most existing approaches for DDI prediction are based on different properties of the
drug compound, such as its chemical structure, side effects, drug-target relationship,
and many more. DDIs can be identified with in vivo models using high-throughput
screening [25]. However, the price of such procedures is relatively high, and testing
large numbers of drug combinations is not practical [23]. To reduce the number of
possible drug combinations, numerous computational approaches have been proposed
[28, 56, 55, 10, 67, 30, 42, 44]. In some of these computational approaches, drugtarget networks are constructed, and DDIs are detected by measuring the strength of
network connections [67], or by identifying drug pairs that share drug targets or drug
pathways, for instance, using the random walk algorithm [30].
Some computational approaches have used the structural similarity and side effect
similarities of drug pairs. For example, Gottlieb et al. proposed the Inferring Drug
Interactions (INDI) method, which predicts novel DDIs from chemical and side effect
similarities of known DDIs [28]. Vilar et al. used similarities of fingerprints, target
genes, and side effects of drug pairs [56, 55]. Cheng et al. constructed features from
the Simplified Molecular-Input Line-Entry System (SMILES) data and side effect
similarity of drug pairs and applied support vector machines to predict DDIs [10].
Zhang et al. constructed a network of drugs based on structural and side effect
similarities and applied a label propagation algorithm to identify DDIs [67]. Recently,
Ryu et al. proposed DeepDDI, a computational framework that calculates structural
similarity profiles (SSP) of DDIs, reduces features using principal component analysis
(PCA), and feeds them to a feed-forward deep neural network [49]. The platform
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generated 86 labeled pharmacological DDI effects, so DeepDDI [26] is basically a
multi-classification (multi-label classification) model.
There are some machine learning–based methods apply KNN[8], SVM [8], logistic
regression [10, 29, 54], decision tree[10], naı̈ve Bayes [10], and network-based label
propagation [67] and random walk [69] or matrix factorization [65]to detect DDIs.
These methods are based on drug properties, such as chemical structure [10, 29, 67,
69, 8], targets [10, 29, 54], Anatomical Therapeutic Chemical classification (ATC)
codes [10, 29, 8], side effects [29, 69, 65].
There is a model developed to predict DDIs based on the Interaction Profile Fingerprint (IPF)[56]. Quite simply, the interaction probability matrix was computed by
multiplying the DDI matrix by the IPF matrix. Afterward,[40] proposed a computational framework by applying matrix perturbation, based on the hypothesis that by
randomly removing edges from the DDI network, the eigenvectors of the adjacency
matrix of the network should not change significantly. These two methods employ no
other data about drugs, except known DDIs.
A new family of similarity-driven methods has followed the assumption that similar drugs should have almost similar interactions. Vilar et al.[19] presented a neighbor
recommender method by utilizing substructure similarity of drugs. Relying on Vilar’s
framework, Zhang et al. constructed a weighted similarity network that is labeled
based on interaction with each of the drugs[67] and applied an integrative label propagation method using a random walk model on the network to estimate potential
DDIs. This prediction framework only considered three types of similarities for predicting DDI via label propagation, namely substructure-based, side effect-based, and
offside effect-based label propagation models[67]. Recently, some methods have also
been proposed for adverse event detection using signals from social media [3, 4, 22].
In recent years, deep learning is becoming a promising technique for automatically
capturing chemical compound features from data sets, and it successfully improves
predictive performance. For example, Harada et al. [51] constructed a dual graph
convolutional neural network to predict DDIs by combining the internal and external
graph structures of drugs to learn low-dimensional representations of compounds.
7
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However, this method works well only for moderately dense chemical networks with
heavy-tailed degree distributions. Wang et al.[60] combined interview information of
drug molecular and intraview of DDI relationships, developing a graph contrastive
learning framework to predict DDIs. Lin et al. [39] merged several data sets into
a vast knowledge graph with 1.2 billion triples, constructing KGNN to resolve the
DDI prediction. On the other side, based on the structural, gene ontology term, and
target gene similarity profiles, Lee et al. [37] applied an autoencoder to reduce the
dimensions of each profile, constructing a DNN model by combining all the reduced
features to predict the types of DDIs. Deng et al. [13] used the chemical substructures,
targets, enzymes, and pathways of drugs to compute a similarity matrix of drugs,
inputting each matrix to a DNN model, and combining the four submodels to predict
DDI events. Besides DDI prediction, deep learning is also successfully applied for
drug–target interaction prediction; for example, Shang et al.[53] develop a multilayer
network representation learning method to learn the feature vectors of drugs and
target. An et al. (An and Yu, [7]) use biased RWR and Word2vec algorithms to
obtain the feature representation of drugs and targets. [63]
In this study, we develop a novel DDI prediction method utilizing the protein
sequence data from the DrugBank and protein structure data from the Protein Data
Bank. We calculate different similarity measures to create the similarity matrices
for each feature attribute. Then, we use the generated feature matrices to create
a single network fusion to measure the potential for interaction between two drugs.
Final decision is performed via the help of a neural network architecture based on
multi-layer perceptrons.
The main novelty of our approach is the focus on only genetic materials (protein
sequence and protein structures) associated with the drug targets in developing our
prediction model. To our knowledge, this is the first attempt at investigating potential
DDI prediction by utilizing only information about the protein sequence and structure
to generate the feature space fed to the neural network.

8

CHAPTER 3
Methodology
We developed a novel neural network model for the prediction of DDIs. The key idea
in our approach is the notion that if two drugs have a similar pattern of similarity
with other drugs, they are likely to have a similar pattern of interacting partners.
To capture the patterns of similarity between drugs, we use information about the
protein sequences and protein structures associated with the protein targets for a
given drug.
Thus, we construct similarity matrices between drugs based on the protein sequences and protein secondary structures and combine these into one protein sequencestructure similarity matrix using network fusion. Fig. 3.4.1 shows a schematic diagram of the general proposed framework.
To calculate the similarity matrices we have used cosine distance, Levenshtein
distance, Jensen Shannon (JS) divergence, and Euclidean Distance as the similarity
measure between a pair of drugs.

3.1

Important Terminologies

Before starting about discussing the process of predicting the drug drug interaction,
we will discuss about some of the basic and important terminologies to proper idea
about the problem we are addressing here.

9
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3.1.1

Drug Protein targets

Drug protein targets are proteins found in the body of living animals that are linked
to specific disorders for which medications are typically used to achieve the desired
therapeutic effect. As a result, in order to be a pharmacological target protein, the
protein must be linked to a disease process. Drug protein targets include enzymes,
receptors, and transporter proteins, however receptors account for the majority of
the targets. There are 1267 therapeutic protein targets that are pharmacologically
active.

3.1.2

Drug Action

The molecular physiological mechanisms by which a chemical creates a response in
living organisms are known as drug action. The alterations we observed after taking
medications are referred to as drug action effects. Penicillin, for example, works
by interfering with bacterial cell wall formation, resulting in the bacteria’s death.
Drugs are mostly utilized to distinguish between normal metabolic processes and any
anomalies that may exist. Because the differences may not be significant, drugs may
work in a non-specific manner, altering both normal and unwanted processes. This
results in unfavorable side effects.

3.1.3

Drug Pairwise Similarity vs Drug Action Similarity

Drug pairwise similarity is a mathematical representation of a relationship between
two pharmaceuticals based on their protein information, which can be either sequence
or structural information, with which two drugs would be similar if they were both
used for the same ailment. We can construct similarity measures between two pharmaceuticals using several levels of information such as chemical structure, pharmacological targets, side-effects, indications, routes, and so on. We employed drug protein
targets to calculate drug pairwise similarity in this paper.
Drug action similarity, on the other hand, is a measure of how similar two medications are in terms of how they affect living creatures. The general drug-cell interaction
10
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can be used to determine the similarity of pharmacological activity. If two distinct
pharmaceuticals have active implications on the same cell, we can say they have similar actions, but that doesn’t guarantee they will have the same type of effect on the
human body.

3.1.4

Drug Similarity space

Drug Similarity space is a feature space of a list of pair of drugs with some attributes
with which we can decide whether a pair of drugs will interact or not. If there is
N number of drugs then we could have N 2 − N possible pairs which might have
interaction between them and might not.

3.1.5

K-mer

A k-mer is just a sequence of k characters in a string (or nucleotides in a DNA
sequence). It is important to remember that to get all k-mers from a sequence you
need to get the first k characters, then move just a single character for the start of
the next k-mer and so on. Effectively, this will create sequences that overlap in k-1
positions.
Decomposing a sequence into its k-mers for analysis allows this set of fixed-size
chunks to be analysed rather than the sequence, and this can be more efficient. Kmers are very useful in sequence matching (string matching with n-grams has a rich
history), and set operations are faster, easier, and there are a lot of readily-available
algorithms and techniques to work with them[9].

3.1.6

Suffix Array

A suffix array is a sorted array of all suffixes of a string. The definition is similar to
Suffix Tree which is compressed trie of all suffixes of the given text. Any suffix treebased algorithm can be replaced with an algorithm that uses a suffix array enhanced
with additional information and solves the same problem in the same time complexity.

11
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In short, the array of indexes to the sorted array of substrings generated during
the transform is essentially a suffix array, which in turn is a representation of the
information in a suffix tree [15].

3.2

Distance Matrices

To estimate the similarity between drugs, we compute distance measures (and sometimes similarity measures) between drugs based on their protein sequences and protein
structure. In the context of data mining, a similarity measure is a distance with dimensions representing object features. When the distance between two items is little,
they are quite similar, however when the distance is large, we will see a low degree
of resemblance. There are several different types of similarity distance metrics. However, we’ll investigate Cosine Similarity, Levenshtein Distance, Jensen Shannon (JS)
Divergence, and Euclidean Distance.

3.2.1

Cosine Similarity (CS)

Cosine similarity metric finds the normalized dot product of two vectors. By determining the cosine similarity, we would effectively try to find the cosine of the angle
between the two objects, when represented as vectors. The cosine of 0° is 1, and it is
less than 1 for any other angle. For two n-length vectors A and B, we have:
Pn
Ai Bi
A.B
CS(A, B) =
= pPn i=12 Pn
2
∥A∥ ∥B∥
i=1 Ai
i=1 Bi

3.2.2

(1)

Levenshtein Distance (L)

The Levenshtein distance is a string metric for measuring the difference between two
sequences. The Levenshtein distance between two strings a, b (of lengths |a| and |b|,
respectively) is given by La,b (|a|, |b|)
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max(i, j)











L(i − 1, j) + 1



La,b (i, j) =
min


L(i, j − 1) + 1











L(i − 1, j − 1) + 1

if min(i,j) = 0
(2)
otherwise

Essentially, La,b (i, j) is the distance between the first i character of a and the first j
character of b.

3.2.3

Jensen Shannon (JS) divergence(JSD)

The Jensen–Shannon divergence is a method of measuring the similarity between two
probability distributions. Given two distributions X and Y , the JS divergence is the
average KL divergence of X and Y from their mixture distribution, M :
1
1
JS(X||Y ) = D(X||M ) + D(Y ||M )
2
2
where M =

3.2.4

X+Y
2

(3)

. and D(X||M ) is the KL divergence between X and M .

Euclidean Distance

This is the basic distance measure, defined as:
v
u n
uX
ED(x, y) = t( (xk − yk )2 )

(4)

k=1

When data is dense or continuous, this is the best proximity measure. The Euclidean
distance between two points is the length of the path connecting them. This distance
between two points is given by the Pythagorean theorem.
Here, we will also give a breif introduction of another distance metric name Tanimoto Coefficient which we use on other type of similarity networks on

13
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3.2.5

Tanimoto Coefficient

Tanimoto coefficient is determined by looking at the number of chemical features that
are common to both molecules (the intersection of the data strings) compared to the
number of chemical features that are in either (the union of the data strings). The
Tanimoto coefficient is the ratio of the number of features common to molecules to
the total number of features. i.e.

T animoto =

(A ∩ B)
(A + B–(A ∩ B))

(5)

The range is 0 to 1 inclusive.

3.3

Similarity Matrices

In most of the DDI prediction methods, its very challenging to finding and developing
the computational approaches which are appropriate drug features. Fort this study,
we consider multiple data sources to collect different types of drug feature information
to calculate the similarity matrices. In our work, we use similarity matrices, rather
than distance matrices. Thus, for each distance measure, we convert the values into
similarity measurement. In this section, we discuss the different types of matrices we
calculated and used in our model evaluation.

3.3.1

Protein Sequence and Structure Similarity Matrices

Each protein structure could have multiple chains. Moreover, each drug active ingredient could have multiple protein targets. Thus, we could compute the similarity
between two drugs (or drug active ingredients) based on the protein chains associated with the respective protein targets for the drugs. For each similarity measure,
we record
1. Minimum Similarity
2. Maximum Similarity
14
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3. Average Similarity(AS)
4. Exponential Weighted Average Similarity(EWAS)
Here, we discuss briefly the protein sequence and protein structure similarity matrices used in this work.
3.3.1.1

Protein Sequence Similarity Matrices

In this approach, the protein Sequence information is used directly to compute the
similarity matrix. We can compute the Levenshtein distance directly. To compute the
cosine, and JS divergence, we will first compute the k-mer profiles for each sequence,
and then compute the similarity measure based on the profile. To generate the k-mer
profiles, we use the suffix array data structure [15].
3.3.1.2

Protein Structure Similarity Matrices

For protein structure, we first covert the protein 3D structure into a protein string
(pString) representation following [16]. The resulting pString is then treated like a
sequence of information for structure. The only difference with the protein sequence
is that each protein structure could have multiple chains(sequences) of information.
We generalized the similarity calculation which will represent the similarity values
between two drug active ingredients (DAIs). We already know that each DAI could
have multiple protein targets. Also, though each protein target has just one sequence,
it could have multiple chains for its 3D structure. Thus, for a given DAI, we capture
its protein structure information as follows:

[R11 , R21 ...Rk11 , R12 , R22 ...Rk22 ...R1M , R2M , ...RkMM ]
where Ri′ s represent the the protein targets, M denotes the total number of protein
targets in the DAI, and k1 , k2 ...kM represent the number of chains on each protein
target.
Now, we can use this generalized DAI representation for similarity calculation
between two DAI’s. If two DAI’s have N and M protein targets and their number
15
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of chains are k1 , k2 , ...kN and L1 , L2 , ...LM respectively, then the possible number of
comparisons would be:

Pc = k1 L1 + k1 L2 + ...k2 L1 + ... + kM LN

(6)

After Pc comparisons at the chain level, we will obtain a vector of similarity values
for the two DAI’s. We use the vector to calculate the minimum, maximum, average
and exponential weighted average similarity between the two DAI’s. The exponential
weighted average is computed as follows:

wi = P

esi
si
i (e )

(7)

Here wi represents weights and si represents a similarity value.
So, we used the minimum, maximum, average, and exponential weighted average
to calculate the similarities each time. As a result, when the similarity values were
determined, the following comparisons in equation 5 occurred on a chain level between
the two medications.
The total number of comparisons would be K1 L1 + K1 L2 + ...K2 L1 + ... + KM LN .
After getting all the quantitative analysis on protein chain level for protein structure data, We use the minimum,maximum,average and weighted average similarity
methods to calculate the similarity values between two drugs.
Each comparison will generate a similarity value s.which I will convert to es So,
the chain level comparison will generate the similarity values below. So weight
esi
P
wi =

(8)

e(esi )

Then the weighted average similarity would be
wi s = w1 s1 + w2 s2 + ... + wl sl

(9)

From the similarity values we will also have minimum similarity mins, maximum
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similarity maxs and average similarity as
mins = min s1 , s2 , ...sl

(10)

maxs = max s1 , s2 , ...sl

(11)

as =

s1 , s2 , ...sl
l

(12)

where l is the number of pair of chains for two Protein structures, So, l = M × N .
After getting the minimum, maximum, average, weighted average from the chain level,
we will now consider drug active ingredients (DAI) level min, max, avg, weighted
average, avg min and avg max. This calculation is normal mathematical min, max
and avg.

3.4

Protein Sequence-Structure Similarity Network
(PS3N)

In Fig 3.4.1, Left hand side of the diagram represents the process of similarity metrics generation. Using the protein sequence, and protein structure similarity matrices,
we generate protein sequence based,and protein structured based similarity networks
using similarity network fusion approach. Each of these networks can be used independently to analyze potential DDIs between drugs or drug active ingredients. To
improve the overall performance, we then integrate the sequence-based similarity network with the protein-based network into one overall similarity network. The result
is the protein sequence-structure similarity network (PS3N). Our network integration
is based on the technique of Similarity Network Fusion(SNF) [21]. SNF is an approach for combining multiple data sources into a single graph representing sample
relationships.
The k-nearest neighbors approach is used in the similarity network construction
and fusion process to down-weight weaker associations between samples. However,
17
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Fig. 3.4.1: Proposed Protein Sequence-Structure Similarity Network (PS3N) model
for predicting adverse drug events. Using the method of Similarity Network Fusion
(SNF) we create a single N ×N fusion matrix for N drugs. From the fusion matrix, we
compute
the feature vectors for each pair of drugs. In this way we will have possible

N
rows, and each row will have N columns as features. These feature vectors are
2
then fed into a multi-layer perceptron model. For protein sequence similarity network,
the number of hidden layers would reduce to 3 since we have less number of drugs.
weak relationships that are consistent across data sources are retained during the
fusion process. The generated integrated network forms the basis for our analysis of
adverse drug events, such as drug-drug interactions.

3.5

Neural Network Model

The model we propose for our problem is entirely reliant on the datasets we’re working
with. That means the neural network’s performance will be influenced by the number
of medications used in the dataset. In our neural network model, we used no more
than four hidden layers. We use Rectified Linear activation function (ReLU) as the
activation function where the dropout rate for each layer would vary from 0.3 to 0.5.
Each of the hidden layers is followed by a dropout layer to avoid over-fitting problems
during the training of the model. The output of each neuron in a layer is a nonlinear
function f of all nodes in the previous layer. f is the ReLU, which is defined as the
positive part of its arguments,

f (x) = x∗ = max{x, 0}

18
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The final output layer is calculated using the sigmoid function:

Sigmoid(x) =

1
1 + e−x

(14)

For each layer, we used Xavier weight initialization, with Categorical cross-entropy
as the loss function which also known as softmax loss. Its a softmax activation plus
a cross-Entropy loss.
Though its normally used for multi-class classification, we used this to maintain
the generality of our prediction. In multi-class classification the labels are one-hot,
so only positive class Cp keeps its term in the loss. There is one element in the target
vector t which is not zero ti = tp . So discarding the elements of the summation which
are zero due to target labels[27], we can write
eSp
)
CE = −log( PC
Sj
j e

(15)

Where, Sp is the CNN score for the positive class.
and Adam Optimizer is used as the optimizer in whcih a learning rate is maintained for each network weight (parameter) and separately adapted as learning folds.
It combines momentum and Root Mean Square propagation (RMSProp) process to
seep up the learning process. If m, v represents the momentum vector and β1 , β2 as
the exponential decay the update rules of Adam would be [14],
mk+1
1 − β1k+1

(16)

v k+1
=
1 − β2k+1

(17)

m̂k+1 =

v̂

k+1

which will finally represents the optimization function as
m̂k+1
θk+1 = θk − η √
v̂ k+1 + ϵ
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CHAPTER 4
Application to Cardiovascular
Drugs
Cardio-oncology is a rapidly evolved field in which patients with cancer with cancer and cardiovascular disease are exposed to complex medication regimens, placing
individuals at increased risk for potential drug interactions (DI’s)[11]. Most cardiovascular and cancer therapies tend to have complex pharmacological profiles, including intrapatient and inter-patient variability, narrow therapeutic index, and a steep
dose-toxicity curve[11]. Annually, 17.9 millions deaths are caused by cardiovascular disease making 31% of all-cause mortality[24]. So patients with cardiovascular
diseases (CVD)n are at high risk of experiencing drug-drug interactions. Because
of multiple etiologies and concurrent comorbidities, CVD patients are treated with
complex therapeutic regimen comprising multiple drugs[5].
As we already have the PS3N model to predict the DDI’s, We could utilize the
model here for a cardiovascular disease problem. So far, we know how to create
similarity networks. But from Drug Bank, Uniprot, SIDER, and other data sources,
there are lot of information available with which more features can be generated.
Here, we will discuss other Drug Similarity profiles calculated based on different
distance metrics and methodologies.
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4.1

Similarity Metrics based on other drug Information

When we create the PS3N model, we only considered protein sequence and protein
structure information to predict the new DDI. However, there is a lot of other important information that have been used by several state-of-the-art algorithms. Though
the way they utilize different drug features were different, that information’s are very
important for drug interaction predictions. We utilize protein-protein interaction,
side-effects, pathways, protein alignments, drug indication, and chemical Structure
information to create a different type of drug similarity profile. Here we briefly discuss
the different types of drug profiling or similarity network generation.

4.1.1

Protein-Protein Interaction (PPI) Network

We use HIPPIE(http://cbdm-01.zdv.uni-mainz.de/ mschaefer/hippie/) data source
to collect the protein-protein interaction data. According to the data, we will have
different PPIs with proteins ids and sequence information. What we did here is to
we consider each interaction between pair of proteins as an edge and store them in a
list. We also find out the unique IDs of proteins here. So from the PPI, we have two
usable data structures,
• Edge List(PPI’s)
• Node list
From the edge list and the node list, we will create a graph which would be a
network of protein interactions. We will utilize all possible pairs of the shortest path
calculation technique to calculate the distances of possible all pairs of proteins. As
we will consider each edge as bidirectional in the graph so if we calculate the distance
between a pair of proteins for example A to B it would be similar for B to A. So, In
this way, we will generate a matrix that represents the minimum distance from any
node to all other nodes in the graph.
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The distance between two proteins should be 0 if there is no potential edge between
them. The two proteins will interact directly if their minimal distance is 1. If the
distance between two proteins is more than one, there will be an indirect contact
between them. We are calling it a hop distance.
After creating the matrix of the protein-protein interaction network, we will utilize
the pathway information to create the mapping from drugs in the pathways to the
PPI matrix.
For each PP interaction, there is a value from the matrix. Suppose one value is
D then consider the following equation as the converter of the hop distance of matrix
into a similarity value S.
−2

Si,j = e−Di,j

(1)

where Di,j = hope distance between the pair of proteins i and j So, after getting
similarity value for each pair, I adjust the minimum, maximum and average for the
drug-drug pair as we calculated for the PS3N.

4.1.2

Pathway Network

For pathway information, we calculated drug-drug edge frequency and protein-protein
edge frequency information from the pathways. And we have a pathway protein distance matrix from which we calculate the distances of direct or hop-based interactions.
For calculating the drug-drug distances using the matrix, we will have a unique list
of drugs from the drug information of pathways. As each drug has multiple proteins
related to them, they will have like (M × N) (M = number of proteins for the first
drug and N = number of proteins for the second drug ) pair of distances from the
matrix. So, from the (M ×N) pair we will calculate the minimum, maximum, and
average similarity. We will also calculate the weighted similarity between drugs.
As the distance matrix contain the hop distance information, we used the following
formula to convert them into similarity.
−2

Si,j = e−Di,j

22

(2)

4. APPLICATION TO CARDIOVASCULAR DRUGS

where Si,j = Similarity between a protein pair i and j. Di,j = hope distance
between the pair of proteins i and j So, after getting similarity value for each pair, we
adjust the minimum, maximum and average for the drug-drug pair.
4.1.2.1

Weighted Similarity of Drug pathway Network

For weighted similarity, we had the protein-protein-edge frequency information but
how we utilize the data in our weighted similarity calculation is a big challenge.
Because till now we only have the frequency for those edges who have the direct
interactions. So, for those who have indirect interaction we need to formulate a way
to find the frequencies so that our weighted similarity would be describable.
Suppose we have two drugs A and B, A has 3 proteins E,F,G and B has 2 proteins
P,Q we will have 3 × 2 = 6 protein pairs (E,P),(E,Q),(F,P),(F,Q),(G,P),(G,Q)
If any pair have direct edge then we will get the frequency from the protein-protein
edge frequency data. But when we don’t have the direct interaction. We consider the
shortest path between them. Suppose between E,Q, we have a path. E → s1 → s2
→Q
There might be other paths as well, but we focus on the shortest path for the
interaction of E and Q. So, to calculate the frequency between E and Q we might
consider the frequency median of E → s1, s1 → s2,and s2 → Q. The median would
be the edge frequency for (E,Q) proteins edge. Now suppose the newly calculated
frequency is f1 Then the equation of weighted similarity would be
W SAB =

X Si,j wi,j
MN
i∈A,j∈B

where wi,j represents the weights and

i,j

(3)

represents the similarity value based on

the hop distance.
In this way we will generate all the similarities for the drug pairs. Directly using
the drug-drug edge information from the pathway to calculate the distance matrix.
Same as the previously mentioned approach.
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4.1.3

Protein-Protein Alignment Similarity Network

In sequence alignments of proteins, the degree of similarity between amino acids
occupying a particular position in the sequence can be interpreted as rough measure
of how conserved a particular region or sequence motif is among lineages.
There are two types of alignments 1. Global 2. Local alignments. Here we mainly
consider global alignment to generate the similarity network. PAM250 matrix[58] is
frequently used to score aligned peptide sequences to determine the similarity of those
sequences. The numbers given above were derived from comparing aligned sequences
of proteins with known homology and determining the accepted point mutation. The
frequencies of these mutations are tabular form as a log odds-matrix where
Mij = 10(log10 Rij )

(4)

Where Mij is the matrix element and Rij is the probability of that substitution
as observed in the database, divided by the normalized frequency of occurrence for
amino acid i. All the number are rounded to the nearest integer. The base-10 log is
used so that the numbers can be added to determine the score of a compared set of
sequences, rather than multiplied.
Using the protein target sequences, we’ll create alignments for paired protein
target sequences using the PAM250 matrix. The alignment score and align length, as
well as the aligned sequences for the pairs, will be returned by the function. We’ll use
the Open Gap and Extend approach to calculate the score. When we find an amino
acid match in a sequence, we assign it an identity score; if we find a mismatch, we
open a gap with a penalty value and expand it with an extending penalty value. It’d
always be a negative number.
We’ll count the number of identity matches from the sequences after we’ve found
the two aligned sequences. To compute the similarity percentage between two sequences, divide the aligned length by the identity score. The ratio of the number of
matching residues to the overall length of the alignment is the similarity percentage.
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4.1.4

Side-Effects Similarity Network

We use the cosine Similarity approach to calculate the similarity value of DAIs in
order to establish a similarity network based on side-effect data. We started by
constructing a list of acronyms for side effects from the dataset. We used a word-tovector method to turn the word information into a vector. We are aware of a variety
of feature extraction methods, such as Bag of Words (BOW) and TF-IDF, among
others. BOW is the most straightforward and intuitive method, involving two types
of calculations. One method is to count the terms in the list of side effect names. The
other is to figure out how often each word appears. The BOW model, on the other
hand, has a problem in that words with a higher frequency dominate word lists, even
if they are unrelated to the other words in the list. That is why we use the TF-IDF
approach in this case. It rescales a word’s frequency based on how many times it
appears across all word lists. Words that are frequently used, such as ”the,” ”that,”
and others, receive a lower score and are penalized.
TF-IDF score of a word w = tf (w) ∗ idf (w) where
tf (w) =

Number of times the word appears in the list
Total number of words in the list

(5)

Number of drugs
Number of drugs that contains word w

(6)

and
idf (w) =

Here, we can see the tf-idf numerical vectors contains the score of each of the words
of side effects in the DAI. So, in this way we will convert the side effects of a given
DAI into numerical features using TF-IDF. We will use cosine similarity function to
compare the first DAI with other DAI in the corpus. The generated result would be
a matrix showing the similarity of each drug to every other drugs.

4.1.5

Chemical Structure Drug Similarity Network

Molecular fingerprints, which record structural information about a molecule as a
series of bits, are commonly used to compute the similarity between two molecules.
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These bits signify the presence or absence of specific patterns or substructures; two
molecules with more of the same patterns will share more bits, suggesting that they
are more similar.
The Pubchempy library has Compound information of each PubChem ID. The
PubChem CACTVS fingerprint is available on each compound using the fingerprint
method. The information I provided about the two DAIs is hexadecimal encoded
representation. We will decode this from hexadecimal and convert them as binary.
Then we will calculate the similarity based on the binary representation of the
molecular fingerprints using the tanimoto coefficient method.

4.2

Protein Sequence, Structure and Chemical Structure Similarity Network (PSSCSSN)

To create the PS3N network, we previously fused protein sequence and protein structure matrices. To develop the final network, we analyzed all forms of similarity
matrices to predict drug interactions in cardiovascular disease. However, there is a
serious issue with data divergence. It was challenging to obtain all forms of information for a medicine because most types of data were acquired from several data
sources. After a thorough examination of all accessible datasets, we discovered that
the Subset of Protein Sequence, Protein Structure, and Chemical Structures has the
most pharmaceuticals for which our neural network model can be trained. We found
722 medicines with all three pieces of information thanks to the interaction of the
three datasets.
So, We consider the Similarity matrices from Chemical Structures, protein Structures, and Protein sequences in SNF[21] approach. By Applying SNF, we finally get
our desired PSSCSSN Network.
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4.3

Neural Network Model

To train the PSSCSSN network for predicting drug-drug interactions in inter cardiovascular drugs and interactions with non-cardiovascular drugs, we have to consider a
neural network model which would take a subset of the network during the training.
This neural network model, like the PS3N model, will be dependent on the amount
of medicines. As a result, the input layer will have 722 Neurons, while the first
concealed levels will have 490 neurons. To avoid the over-fitting problem during
training, there will be a dropout layer with a comparable dropout rate as before. As
the activation layer, the ReLU was utilized. The number of layers increases to 300 in
the second concealed layer. The third concealed layer will contain 150 neurons, while
the fourth layer will have 50 neurons. The loss function in this model is Categorical
Cross Entropy. The Adam optimizer is the optimization function that begins training
with the default learning rate. The Sigmoid function is used as the output layer of
the model.
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CHAPTER 5
Experiments and Results
For the development of the PS3N model to predict effectively the DDI’s, we put
significant time on data processing and cleaning. Our whole experimental setup is
divided into multiple parts. Before going to the experiments and results here is a
brief introductions to the datasets we utilize to prepare our similarity matrices.

5.1

Datasets

In this work, we use different sources for different types of drug information. Most
of the information’s like Protein Sequence, Pathways are extracted from Drug Bank
(https://go.drugbank.com/).
The second is the protein structure dataset retrieved from RCSB Protein Data
Bank (https://www.rcsb.org). Protein chains are extracted from each PDB file using biopython libraries. We combined these for a dataset of 905 drugs (active ingredients) in DrugBank with information on both protein structure and protein sequences.The side-effects and indications infromation of drugs were collected from
SIDER (http://sideeffects.embl.de/) database. Protein-Protein Interaction infromation were collected from Uniprot (https://www.uniprot.org/uniprot/) portal. Lastly,
We also evaluated our methods using the DS1 and DS2 datasets reported in [41].
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5.2

Performance Evaluation of PS3N Model

To evaluate the performance of the proposed method, we compared it with machine learning approaches such as KNN (K-Nearest Neighbor), RF (Random Forest), Logistic Regression, LDA (Linear Discriminant Analysis), and Support Vector
Machine. We also compared our results with state of the art methods proposed in
[41],[56],[67],[68]. We evaluated the competitiveness of our models using different
performance metrics such as Precision, Recall, F1, Area under Curve (AUC), and
AUPR. Here, I am briefly providing the calculation approach for each of the performance metrics.

P recision =
recall =
F − measure =

TP
TP + FP

(1)

TP
TP + FN

(2)

2.precision.recall
precision + recall

(3)

Where TP, TN, FP, and FN stand for True Positive, True Negative, False Positive,
and False Negative. Precision is the fraction of correct predicted interactions among
all predicted interactions. while recall is the fraction of correct predicted interactions
among all true interactions. Precision and recall have a trade-off thus improving one
of them may lead to a reduction in another. Therefore, utilizing F-measure which is
the geometric mean of precision and recall is more reasonable.
We note that if the interaction between two drugs is assigned to zero, it simply
implies that no evidence of their interaction has been found yet. The two may still
interact, but the features we have used so far are not able to detect that.
Thus, they may interact with each other. So we cannot identify TN and FP
pairs correctly. The training process requires both positive and negative samples.
Therefore, some of the zero assigned pairs are considered as non-interactive pairs in
the training model. So every method may have some FP in its evaluations. This
leads to a reduction in calculated precision and F-measure, while the real values of
precision and F-measure may be higher. Since the values of precision, recall, and
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F-measure is dependent to the value of the threshold, we also evaluate methods via
AUC which is the area under the receiver operating characteristic (ROC) curve.
We note that if the interaction between two drugs is assigned to zero, it simply
implies that no evidence of their interaction has been found yet. The two may still
interact, but the features we have we have used so far are not able to detect that.

5.2.1

Experimental setups

For our training experiment, we split each dataset into training, validation,and test
sets according to a 70% − 10% − 20% random split. For each dataset, networks were
trained on the training set for a total of 100 epochs with a batch size of 100 for the
proposed neural network method.
To initialize the weights of the network so that the neuron activation function
can avoid saturation problems or being stuck into dead regions. We used batch size
of 100 and 20 - 50 epochs, with Categorical cross entropy and Adam Optimizer for
optimization with a momentum parameter 0.9. The epoch number was set to 20 and
50. We use Categorical cross entropy and Adam optimizer for optimization with a
momentum parameter 0.9.

5.2.2

Comparing performance with State-of-the-art Algorithms

We evaluated our model on the single feature matrices to identify the contribution of
specific features to the performance of the model. We used the average and exponential weighted average similarity measures to generate the similarity matrices. Table
5.2.1 shows the performance of the proposed model using protein sequences. Table
5.2.2 shows results using protein structure.
In Table 5.2.4 and 5.2.5 we compare our results with the existing state-of-the-art
algorithms and found significant improvements in terms of AUC, Precision, and Recall. We considered DS1 and DS2 datasets from [41] to compare the performance
of existing methodologies. From the two datasets, we could generate the protein sequence and structure metrics for a subset of drugs. We used the newly generated
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Table 5.2.1: Performance of PS3N using similarity matrices based on protein sequences

Feature name

Precision

Recall

F-measure

AUC

Accuracy

L AS

0.9199

0.9419

0.9308

0.9673

0.9081

JSD AS

0.8837

0.8667

0.8751

0.9181

0.8377

CS AS

0.8799

0.9093

0.8943

0.9315

0.8590

L EWAS

0.9499

0.9638

0.9568

0.9832

0.9429

JSD EWAS

0.9406

0.8835

0.9112

0.9559

0.8870

CS EWAS

0.9523

0.9632

0.9578

0.9833

0.9443

L = Levenshtein, JSD = JS Divergence, CS = Cosine, AS = Average
Similarity, EWAS = Exponential Weighted Average Similarity

feature space in our model to check the performance and showed significant improvement in both cases. From Table 5.2.4, we can see that the PS3N showed better
performance when compared to the other methods. However, it showed similar results on the datasets based on sequence, structure, or both information. This also
holds in Table 5.2.5 which was created from the DS2 dataset.

5.2.3

Predicted DDI Network Diagram Using PS3N

We quantified all the drug-drug interactions using the PS3N model in Fig. ??. As
a result, when we anticipate drug interactions between pairs of pharmaceuticals, the
model generates a likelihood of interaction between the drugs, which we refer to as
an interaction score, which ranges from 0 to 1. We can also use the model to get the
projected labels for the test data. To prepare network data, the pharmaceutical Ids
are employed as network nodes. We considered a pair of drugs to have an advantage
if the expected labels from the model were 1. We discovered that the network data
contained a wealth of interaction information. We proposed imposing a threshold on
the principal Similarity network to eliminate some data from consideration to improve
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Table 5.2.2: Performance of PS3N using similarity matrices based on protein structure.

Feature name

Precision

Recall

F-measure

AUC

Accuracy

JSD AS

0.8796

0.9279

0.90313

0.9171

0.8564

CS AS

0.9037

0.9469

0.9248

0.9499

0.8889

JSD EWAS

0.9762

0.9650

0.9706

0.9895

0.9578

CS EWAS

0.9743

0.9738

0.9741

0.9910

0.9627

*L = Levenshtein, JSD = JS Divergence, CS = Cosine, AS = Average
Similarity, EWAS = Exponential Weighted Average Similarity

Table 5.2.3: Results using combined protein sequence and protein structure similarity
matrices.

Method

Precision

Recall

F-measure

AUC

Accuracy

PS3N

0.9800

0.9818

0.9809

0.9946

0.9725

RF

0.7812

0.7241

0.7516

0.8089

0.8354

SVM

0.5507

0.2076

0.3015

0.5711

0.7320

LR

0.5169

0.1586

0.2427

0.5506

0.7243

LDA

0.5302

0.1740

0.2620

0.5572

0.7269

KNN

0.5470

0.6196

0.5810

0.7107

0.7510

Decision Tree

0.7134

0.7008

0.7071

0.7961

0.8382

NDD

0.5646

0.1927

0.2874

0.7366

0.7311
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Table 5.2.4: Performance comparison of different methods on DS1 from [41]. We
obtained information on 469 drugs for protein sequences, and on 414 drugs for protein
structure. The first Six rows are from [41] to compare the results from our model
Method

AUC

AUPR

F-measure

Recall

Precision

Substructure-based label propagation model [67]

0.937

0.901

0.804

0.797

0.811

Side-effect-based label propagation model [67]

0.936

0.903

0.806

0.793

0.820

Offside-effect-based label propagation model [67]

0.937

0.904

0.809

0.795

0.823

Vilar’s substructure-based model [56]

0.936

0.902

0.804

0.797

0.812

Classifier ensemble method [68]

0.956

0.928

0.836

0.827

0.843

Weighted average ensemble method [68]

0.948

0.919

0.831

0.835

0.826

NDD [41]

0.954

0.922

0.835

0.836

0.833

PS3N (Protein Sequence)

0.974

0.948

0.916

0.925

0.906

PS3N (Protein Structure)

0.972

0.949

0.917

0.932

0.903

PS3N (Sequence + Structure)

0.972

0.948

0.917

0.931

0.903

presentation. We can see that several interactions have been discovered in Fig.??,
but they are all the same shade. Our primary goal was to see if the model could do
DDI prediction with the maximum level of accuracy. When we applied the threshold
to the network’s similarity values, we discovered that 89 percent of the interactions
have the correct labels. When we looked at the entire network, however, performance
rose by about 96 percent. Even if some of the estimated values have a similarity of
less than 0.70, they nonetheless had interactions.

5.3

Impact of algorithmic parameters

Table 5.3.1 shows the impact of different hyperparameters on the performance of
the proposed model. From the table, Adam Optimizer with a learning rate of 0.01
produced the best overall result. SGD Optimizer for learning rate 0.05, 0.01 and 0.10
showed almost similar accuracy level as we got for Adam optimizer. In our proposed
neural network model, the number of hidden layers will vary based on the number
of drug active ingredients (DAI’s) on the datasets. Normally, for protein sequence
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Table 5.2.5: Performance comparison of different methods on the DS2 Dataset from
[41]. We obtained information on 585 drugs for protein sequences, and on 504 drugs
for protein structure. The first Six rows are from [41] to compare the results from
our model
Method

AUC

AUPR

F-measure

Recall

Precision

Substructure-based label propagation model [67]

0.788

0.208

0.294

0.537

0.197

Vilar’s substructure-based model [56]

0.810

0.244

0.312

0.479

0.232

Classifier ensemble method [68]

0.936

0.487

0.553

0.689

0.462

Weighted average ensemble method [68]

0.646

0.440

0.15

0.226

0.118

NDD [41]

0.994

0.890

0.825

0.804

0.847

PS3N (Protein Sequence)

0.998

0.975

0.978

0.987

0.972

PS3N (Protein Structure)

0.997

0.975

0.978

0.992

0.964

PS3N (Sequence + Structure)

0.997

0.970

0.977

0.987

0.970

dataset, it will not more than 4. For Protein structure or the combination of both, it
will be between 3 to 5.
In our proposed approach, similarity network fusion(SNF) used for final matrix
creation of each datasets. We had different distance measures, for each of the distances
we had one matrix. from the matrices we create the fusion matrix. During the creation
of the network, some parameters were used which played a role to the similarity
matrix construction. In the SNf method, a distance metric was considered, we used
the default euclidean distance metric. And there were two other parameters muweighted k-nearest neighbors kernel to the distance matrix to calculate the similarity
fusion matrix. We used different values in range of 0.3 to 0.5 for mu and 10 to 20 for
k. we found that for mu = 0.3 and k = 10 works better for the performance of the
model. So the generated fusion network with the parameter setup works better than
the others.
In the deep neural network model, we used 3 to 5 hidden layers based on the
number of drug active ingredients presents on the datasets. However in our proposed
PS3N model we used he normal distribution for the layer initialization when we used
ReLU as the activation function in the layer. We used he normal because we used
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Fig. 5.2.1: Drug Drug Interaction Similarity Network Diagram. We have used a
threshold value ≥ 0.7 in PS3N Network to discard a large chunk of network diagram.
If Any pair of drugs have predicted labels as 1, we consider an edge between the drugs.
In these way we created a Network diagram for PS3N Model using PS3N Network.

Table 5.3.1: Results of PS3N with variation on algorithmic parameters.
Optimizer

Learning rate

Accuracy

Adam optimizer

0.05

0.7200

Adam optimizer

0.10

0.7213

Adam optimizer

0.01

0.9710

SGD

0.05

0.9646

SGD

0.10

0.9644

SGD

0.01

0.9637

RMSProp

0.01

0.7210
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ReLu as activation. In the final layer where we used glorot normal distribution for the
layer initialization because Sigmoid function used as the activation function. Though
different initialization have very little impact on the performance, we select this as
general set up for the experiment.
Then we used the dropout value with a range of 0.2 to 0.5 for each of the layer. 0.3
showed best outcome in the model performance. Then in the model optimization we
used different optimization techniques like Stochastic gradient descent (SGD), Adam
optimizer, RMSProp etc in which Adam and SGD have close performance but in
RMSProp the algorithm performance decreases significantly.
In gradient calculation, learning rate is very important. In our experimental setup
we choose different learning rate in a range from 0.001 to 0.1. We also use weight
decay for the gradient update in a range from 1e− 4 to 1e− 8. But we found out the
best value of weight decay for the model is 1e− 6. After different selection of learning
rate we found that 0.01 give us the best result for the model.

5.4

Results on Cardiovascular Drugs

To check the performance of the PSSCSSN model, we compared this new model
with our PS3N. In Table 5.4.1, we can see that there are different PS3N variations.
Basically, all the variations are representing different data sets.
In this experimental setup, we first considered evaluating the performance of the
PS3N model on different datasets. Though the PS3N model is based on protein
sequence and protein structure similarity network. We utilize the neural network
model for other data sets like side-effects, pathways, protein-protein interactions, and
chemical structures. To keep in mind the dependency on the drug numbers we have to
adjust the input layer and hidden layer numbers for side effects and chemical structure
data. there is 936 drugs’ side-effect information available from which the side-effect
similarity network was calculated. On the other hand, the similarity network for
Chemical structure has 1461 drugs into consideration. So the two different networks
had a little different architecture in terms of hidden layers, but maintain the core
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Table 5.4.1: Performance comparison of PS3N model and PSSCSSN model.
Method

Precision

Recall

F1-measure

AUC

Accuracy

PS3N (pathways)

0.923

0.96

0.942

0.974

0.922

PS3N(Side-Effects)

0.895

0.921

0.908

0.951

0.883

PS3N(Chemical Structure)

0.964

0.983

0.974

0.991

0.964

PS3N (Protein Sequence)

0.998

0.975

0.978

0.987

0.972

PS3N (PPI)

0.958

0.967

0.962

0.979

0.954

PS3N (Protein Structure)

0.997

0.975

0.978

0.992

0.964

PS3N (Sequence + Structure)

0.997

0.970

0.977

0.987

0.970

PSSCSSN

0.981

0.970

0.975

0.974

0.970

design of the PS3N model. So we can call them variations of PS3N.
In 5.4.1 we can see that PS3N is performing better for most of the cases in terms
of all performance metrics. If we consider accuracy metrics for the DDI prediction,
PS3N (Sequence) is better than all other variations but we can say PSSCSSN and
PS3N ( Sequence + Structure) are pretty close in terms of accuracy metrics. However,
we designed the PSSCSSN model only because we have a large subset of information
from all the available datasets. Our main goal is to identify as much as possible to
find the unknown DDI for the cardiovascular drugs and create a knowledge base from
the given network information.

5.4.1

Predicted Interactions of cardiovascular drugs

Our model is building a database of pharmacological interactions, which we will use
to better understand the systemic effects on cardiovascular disease. On the level of
sequence and structure, the PSSCSSN model provides a different quantitative analysis
of similarity values and their intended protein targets. Most importantly, we were
able to predict the DDIs for both inter-cardiovascular medication interactions and
cardiovascular-non-cardiovascular drug interactions using the model. Our projected
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Table 5.4.2: Sample of predicted new DDI’s for cardiovascular drugs using PSSCSSN
Model
Drug Name

# Non-cardiovascular DDI’s

# Cardiovascular DDI’s

% of overall interactions

% of cardiovascular DDI’s

Pravastatin

176

18

6.38

0.65

Atorvastatin

79

9

2.86

0.32

Lovastatin

157

23

5.69

0.83

Spironolactone

135

4

4.89

0.14

Terazosin

100

3

3.62

0.10

Niacin

62

9

2.24

0.32

Cerivastatin

126

14

4.56

0.51

Dofetilide

125

22

4.52

0.81

Ticlopidine

81

12

2.93

0.43

Clofibrate

122

17

4.42

0.62

Telmisartan

89

3

3.23

0.10

Quinapril

80

4

2.89

0.14

Argatroban

76

16

2.75

0.58

DDIs reveal a plethora of novel medication interactions.
We can see some quantitative analysis of the interactions in Table. 5.4.2. We
received a total of 2759 new DDIs from the PSSCSSN network. There are options
for both types of interactions. Pravastatin, with a total of 6.38 % new interactions,
has the highest number of new interactions. Interactions with inter-cardiovascular
medicines account for only 0.65 % of those interactions.
For example, drugs like hydrocortamate and olanzapine interact with Pravastatin,
causing dizziness, restlessness, depression, low blood pressure when standing, and
other side effects. As a result, cardiovascular patients who take those medications for
skin illnesses or mental health could be jeopardizing their overall health.
In Table 5.4.3, we can see a comprehensive representation of all the interactions
found for inter cardiovascular DDI’s. The table represents a greater knowledge base
for this CVD problem. There is a lot of information we can get from this table. It’s
showing some surprising results when we look at the interactions between cardiovascular drugs and other drugs, because many common cardiovascular drugs interact
with other CVD drugs, but there is no interaction netween them. For example,
if we look into the CVD drug Fenofibric Acid, we can see that there is only one
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inter cardiovascular drug interaction with Candesartan. But when we looked into
DDI’s for other cardiovascular drugs we found Clopidogrel, Dronedarone, Ticagrelor,
Donepezil, Benazepril,Dipyridamole, Olmesartan, Argatroban, Quinapril, Telmisartan, and Dofetilide interacting with Fenofibric Acid. There are several examples like
this. So, this knowledge base could be vital to identifying the several relations among
different drugs and their adverse reactions to the patients.
Table 5.4.3: Discovered new Inter cardiovascular DDI’s using PSSCSSN Model.
Drug Name

Pravastatin

#

interacted cardiovascular drugs

%

Cardio-

cardio-

vascular

vascular

DDI’s

DDI’s

18

Ticlopidine;

Milrinone;

Disopyramide;

0.65

Ibutilide; Diltiazem; Amlodipine; Triamterene;

Benazepril;

Fondaparinux;

Eplerenone; Perindopril; Irbesartan; Terazosin; Hydralazine; Prasugrel; Azilsartan
medoxomil; Aliskiren; Enalaprilat
Atorvastatin

of

9

Papaverine; Terazosin; Propafenone; Prasugrel; Azilsartan medoxomil; Aliskiren;
Vorapaxar; Edoxaban; Enalaprilat

39

0.32
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Lovastatin

23

Milrinone; Disopyramide; Ibutilide; Amlodipine;

Triamterene;

0.83

Bendroflumethi-

azide; Trandolapril; Benazepril; Fondaparinux; Niacin; Guanabenz; Moexipril;
Perindopril; Quinapril; Dopamine; Hydrochlorothiazide; Guanfacine; Papaverine;

Terazosin;

Azilsartan medoxomil;

Aliskiren; Edoxaban; Enalaprilat
Spironolactone

4

Niacin; Clofibrate; Dronedarone; Tica-

0.14

grelor
Terazosin

3

Gemfibrozil; Prasugrel; Pitavastatin

0.10

Niacin

9

Guanabenz;

0.32

Verapamil;

Clopidogrel;

Perindopril; Telmisartan; Dipyridamole;
Guanfacine;

Terazosin;

Hydralazine;

Prasugrel; Ticagrelor; Aliskiren
Cerivastatin

14

Fosinopril; Trandolapril; Benazepril; Gua-

0.51

nabenz; Moexipril; Lisinopril; Perindopril;
Dopamine; Guanfacine; Papaverine; Hydralazine; Ticagrelor; Azilsartan medoxomil; Aliskiren
Dofetilide

22

Milrinone; Trandolapril; Benazepril; Fondaparinux; Enalapril; Guanabenz; Simvastatin; Perindopril; Donepezil; Quinapril;
Pindolol; Telmisartan; Methyldopa; Guanfacine; Atorvastatin; Gemfibrozil; Prasugrel; Pitavastatin; Aliskiren; Sacubitril;
Fenofibric acid; Candesartan
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Ticlopidine

12

Olmesartan;

Trandolapril;

Benazepril;

Enalapril;

Moexipril;

Eprosartan;

0.43

Quinapril; Telmisartan; Papaverine; Captopril; Azilsartan medoxomil; Aliskiren
Clofibrate

17

Losartan;

Moexipril;

Perindopril;

Donepezil;

Quinapril;

Telmisartan;

Dipyridamole;

Guanfacine;

Papaverine;
Hydralazine;

0.62

Irbesartan;

Propafenone;

Sitagliptin;

Azilsartan

medoxomil;

Aliskiren;Enalaprilat; Candesartan
Telmisartan

3

Fluvastatin; Ticagrelor; Fenofibric acid

0.10

Quinapril

4

Atorvastatin;

Pitavastatin;

0.14

Ibutilide; Diltiazem; Fosinopril; Niacin;

0.58

Ticagrelor;

Fenofibric acid
Argatroban

16

Losartan; Eplerenone; Perindopril; Acetazolamide; Telmisartan; Propafenone;
Gemfibrozil;

Azilsartan

Pitavastatin;

medoxomil;

Aliskiren;Enalaprilat;

Fenofibric acid
Fondaparinux

9

Guanabenz; Clofibrate; Donepezil; Telmis-

0.33

artan; Atorvastatin; Fluvastatin; Terazosin; Propafenone; Aliskiren
Olmesartan

10

Ibutilide;

Clofibrate;

Donepezil;

Fluvastatin;

Acetazolamide;
Gemfibrozil;

Sitagliptin; Prasugrel; Ticagrelor; Fenofibric acid
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Acetazolamide

12

Eprosartan;

Telmisartan;

Irbesartan;

Fluvastatin;

Papaverine;

Terazosin;

0.435

Propafenone; Apixaban; Ticagrelor; Azilsartan medoxomil; Pitavastatin; Aliskiren;
Bendroflumethiazide
8

Niacin; Clofibrate; Simvastatin; Acetazo-

0.29

lamide; Atorvastatin; Fluvastatin; Rosuvastatin; Pitavastatin;
Benazepril

7

Niacin;

Clofibrate;

Donepezil;

Acetazolamide;

Fluvastatin;

0.25

Gemfibrozil;

Fenofibric acid;
Disopyramide

7

Trandolapril;

Clofibrate;

Simvastatin;

Telmisartan;

Irbesartan;

Atorvastatin;

0.25

Aliskiren;
Rosuvastatin

6

Papaverine; Terazosin; Propafenone; Azil-

0.21

sartan medoxomil; Aliskiren; Enalaprilat;
Moexipril

6

Acetazolamide;

Donepezil;

Fenofibrate;

0.21

Fluvastatin; Gemfibrozil; Ticagrelor;
Hydrochlorothiazide6

Irbesartan; Fluvastatin; Captopril; Hy-

0.21

dralazine; Pitavastatin; Aliskiren;
Clopidogrel

6

Perindopril; Acetazolamide; Methyldopa;

0.21

Terazosin; Aliskiren; Fenofibric acid;
Valsartan

5

Ibutilide; Amlodipine; Niacin; Clofibrate;

0.18

Aliskiren;
Ibutilide

5

Niacin; Guanabenz; Fluvastatin; Terazosin; Pitavastatin;
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Donepezil

5

Dopamine;

Terazosin;

Hydralazine;

0.18

Clofibrate; Donepezil; Fluvastatin; Pra-

0.14

Aliskiren; Fenofibric acid;
Guanabenz

4

sugrel;
Milrinone

4

Niacin; Fluvastatin; Propafenone; Tica-

0.14

grelor;
Ticagrelor

4

Aliskiren; Sacubitril; Enalaprilat; Fenofib-

0.14

ric acid;
Papaverine

3

Prasugrel; Ticagrelor; Pitavastatin;

0.10

Fenofibrate

3

Papaverine; Terazosin; Azilsartan medox-

0.10

omil;
Aliskiren

3

Vorapaxar; Edoxaban; Fenofibric acid;

0.10

Fluvastatin

3

Papaverine;

Azilsartan

medoxomil;

0.10

Azilsartan

medoxomil;

0.10

Aliskiren;
Gemfibrozil

3

Ticagrelor;
Aliskiren;

Simvastatin

3

Dopamine; Sitagliptin; Aliskiren;

0.10

Pitavastatin

3

Aliskiren; Vorapaxar; Enalaprilat;

0.10

Dipyridamole

2

Dopamine; Fenofibric acid;

0.072

Trandolapril

2

Simvastatin; Fluvastatin;

0.072

Eprosartan

2

Prasugrel; Ticagrelor;

0.072

Lisinopril

2

Fluvastatin; Ticagrelor;

0.072

Dronedarone

2

Azilsartan medoxomil; Fenofibric acid;

0.072
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Pindolol

2

Rosuvastatin; Ticagrelor;

0.072

Rivaroxaban

2

Pitavastatin; Aliskiren;

0.072

Captopril

2

Prasugrel; Ticagrelor;

0.072

Guanfacine

2

Fluvastatin; Ticagrelor;

0.072

Apixaban

2

Aliskiren; Enalaprilat;

0.072

Hydralazine

1

Ticagrelor;

0.036

Triamterene

1

Niacin;

0.036

Amlodipine

1

Niacin;

0.036

Labetalol

1

Rosuvastatin;

0.036

Sotalol

1

Fenofibrate;

0.036

Dopamine

1

Atorvastatin;

0.036

Sitagliptin

1

Aliskiren;

0.036

Fosinopril

1

Ticagrelor;

0.036

Esmolol

1

Gemfibrozil;

0.036

1

Pitavastatin;

0.036

Fenofibric acid

1

Candesartan;

0.036

Ramipril

1

Fluvastatin;

0.036

Isradipine

1

Fluvastatin;

0.036

Perindopril

1

Ticagrelor;

0.036

Diltiazem

1

Acetazolamide;

0.036

Azilsartan

me-

doxomil
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Fig. 5.4.1: PS3N network diagram for the cardiovascular drugs. In this network, there
are only 87 cardiovascular drugs are available among the 489 drugs we considered for
the network diagram. This network is representing the overall interactions based on
PS3N network. The red lines are indicating the new interactions.
5.4.1.1

PS3N DDI Network for cardio vascular drugs

To visualize the performance of the PS3N network on cardiovascular drugs, we considered a subset of protein sequence and protein structure networks into consideration to
predict their labels. After calculating the network information like the predicted labels, cardiovascular interactions, and non-cardiovascular interactions, We can see the
overall interactions in 5.4.1. the gray regions are representing all possible DDI’s available or known to us. The red dotted lines are showing newly predicted interactions
among different drugs.
As the visualization for this big graph is difficult to find out specific information
for individual drugs, we showed an example in 5.4.2 to get some idea about how we
can utilize our model to find out the specific queries regarding drug interactions. In
this example, we can see that Alteplase (popularly used for cardiovascular disease to
dissolve blood clots) is interacting with drugs like hydrochlorothiazide which normally
increase blood pressure and that is not good for cardiovascular patients.
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Fig. 5.4.2: This diagram is representing the network for drug Alteplase. The green
node representing Alteplase and the red dotted lines are representing the new intercardiovascular drug interactions. Among the 87 cardiovascular drugs, there are new
6 interactions for Alteplase.
5.4.1.2

PSSCSSN DDI Network for cardiovascular drugs

In the PSSCSSN model, there are three different types of information were utilized to
create the similarity network. So when we check the model performance in visualization, there are lots of new interactions found. As we got some statistical idea about
this on Table. 5.4.2. Here we will explore the newly discovered interactions in Fig.
5.4.3, which is representing a circular interaction diagram. the center of the diagram
represents the drug Pravastatin and all other nodes have edges from the center. we
can see 176 different edges showing newly discovered interactions with the drug.
In Fig. 5.4.4, there are information’s about inter-cardiovascular drugs for Pravastatin. There are different edge attributes are available for this as well such as numerical values of similarities which could potentially be used for identify different aspects
of DDI’s like severity, causality, etc.
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5. EXPERIMENTS AND RESULTS

Fig. 5.4.3: PSSCSSN Network diagram for a particular cardiovascular drug Pravastatin. The network contains an overall 722 drugs. It is very difficult to show every
interactions from all the nodes. So we considered a subset of interactions which
are newly found and interacting with Pravastatin.Green lines represents the intercardiovascular interactions with Pravastatin

Fig. 5.4.4: Cardiovascular interaction diagram for Pravastatin. All other drugs interactions are discarded for better visualization and understanding
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CHAPTER 6
Discussion
The main objective of this work is to propose a new computational model for DDI
prediction utilizing the genetic information about drug protein targets. Our work has
given a promising direction for addressing DDI prediction problems. We showed different ways of creating the feature space to identify the interaction between a pair of
drugs. Roughly, we identified drugs with information on protein structures, and drugs
with information on the protein sequence. We created the labeled feature space by
utilizing the interaction information available in DrugBank. The combination of the
structure and sequence information resulted in 904 drugs. Unlike previous methodologies, we considered only protein sequence and structure similarity networks for
the first time to predict drug interactions. In addition, our similarity network computation technique allows extracting important protein features in terms of different
distance measures.
Our proposed model for cardiovascular drug interactions is likely the first to take
into account all sorts of interactions in cardiovascular issues. Most of them worked
on patent information, utilizing multiple-coexisting patient circumstances on cardiovascular disease, according to our findings in a literature analysis on cardiovascular
drug interactions. Those studies largely looked at common drugs to discover their
clinical importance and explanation. In terms of similarity values, our suggested
method considers 722 pharmaceuticals with a knowledge base of protein sequence,
protein structure, and chemical structure. We were able to generate network data
from the prediction as well. This vast amount of information could be crucial for
future cardiovascular disease studies.
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6. DISCUSSION

The major drawback of our work is the lack of availability of drug information.
Due to the different sources, it’s difficult to get all types of information for the same
drug. As we mainly focused on Drugbank and Protein Data Bank (PDB) with a
focus on SIDER and HIPPIE for Side-effects and PPI, It was a challenge to find the
commonality between the different datasets. Moreover, the datasets have significantly
more unknown interactions than known interactions. Thus, this creates a problem
of data imbalance, especially if we do not consider appropriate thresholds for the
unknowns. However, the time and space complexity for feature space generation is
significant and that will need to be addressed in the future.
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CHAPTER 7
Conclusion
In this study, we proposed a novel drug-drug interaction detection mechanism. The
proposed model is divided into three major chunks. The first is focused on building
the similarity profiles from Drug Bank and PDB. The second is the creation of an
integrated similarity network (PS3N) about drugs, using information about their
protein targets, namely, the protein sequences and protein structures of such targets.
The third component is how information from the integrated network is used to
develop a deep neural network model for improved prediction of the potential drug
interactions. We compare the results produced using the proposed PS3N in a deep
learning framework with results from other recent machine learning-based approaches.
The comparisons showed that our proposed methodology is quite competitive with
respect to the state-of-the-art, at times outperforming the state-of-the-art methods.
Though the computational complexity is high for the pre-processing, there are still
opportunities to improve the performance of the model and also improve the datasets
as well. In our proposed methodology, we showed a new approach to dealing with
the DDI prediction problem, by exploiting genetic information about the drug protein
targets, in particular, information about their protein sequence and protein structure.
After that, we created the PSSCSSN model for cardiovascular medications in order
to find previously unknown drug interactions. The PSSCSSN model was created using
protein sequence, protein structure, and chemical structure drug similarity networks.
We were able to find a considerable number of previously unreported interactions
with cardiovascular medications using our proposed approach. Interactions with noncardiovascular medicines were also detected using the model.
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7. CONCLUSION

The PSSCSSN model has generated a knowledge base for cardiovascular drug
interactions, which could aid cardiovascular disease research in a variety of ways,
including clinical decision making, pharmacist training, and electronic prescription
to reduce patent risk. Future research could look into how the general approach
could be applied to other adverse drug effects besides DDIs. Also, with a complete
understanding of various drug-drug interactions, the work might be expanded to
assess the frequency, level, and risk factors of cardiovascular disease patients. Using
the PS3N and PSSCSSN models, we hope to locate COVID-19 and learn more about
the negative effects of immunizations and other medications.
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